Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS THOUSAND OAKS, Calif. (Aug. 5, 2025) - Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2025. "We're delivering strong performance and reaching more patients with innovative medicines and biosimilars that address serious diseases. We continue to invest in science that enables longer, healthier lives and supports ...

Core Insights - Amgen reported strong financial performance for Q2 2025, with total revenues increasing by 9% to $9.2 billion compared to Q2 2024, driven by a 13% volume growth in product sales, despite a 3% decrease in net selling price [5][20] - The company continues to focus on innovative medicines and biosimilars, aiming for sustainable long-term growth [2] Financial Performance - Total revenues for Q2 2025 reached $9.2 billion, a 9% increase from Q2 2024 [5] - GAAP earnings per share (EPS) rose 92% from $1.38 to $2.65, while non-GAAP EPS increased 21% from $4.97 to $6.02 [5][16] - GAAP operating income increased from $1.9 billion to $2.7 billion, with an operating margin of 30.3%, up 6.6 percentage points [5][15] - Free cash flow for Q2 2025 was $1.9 billion, down from $2.2 billion in Q2 2024, influenced by deferred tax payments and higher capital expenditures [20] Product Sales Performance - Product sales grew by 9%, with 15 products achieving double-digit sales growth, including Repatha® (31% increase), EVENITY® (32% increase), and UPLIZNA® (91% increase) [5][6] - Prolia® sales decreased by 4% year-over-year to $1.1 billion, attributed to lower net selling prices [6][12] - TEZSPIRE® sales increased by 46% year-over-year to $342 million, driven by volume growth [12][13] Operating Expenses and Margins - Total operating expenses increased by 1% year-over-year, with R&D expenses rising by 21% due to investments in clinical programs [14][15] - The operating margin on a non-GAAP basis increased to 48.9%, reflecting improved operational efficiency [15][19] Cash Flow and Balance Sheet - Operating cash flow for Q2 2025 was $2.3 billion, down from $2.5 billion in Q2 2024 [18] - Cash and cash equivalents totaled $8.0 billion, while debt outstanding was $56.2 billion as of June 30, 2025 [20] Guidance - For the full year 2025, Amgen expects total revenues to be in the range of $35.0 billion to $36.0 billion [18]

Industry Overview - The second-quarter earnings season for the drug and biotech sector is in full swing, with major companies like Pfizer, Eli Lilly, Amgen, Gilead Sciences, and Novo Nordisk set to announce results [1] - The earnings season began mid-July with Johnson & Johnson reporting strong results, exceeding estimates for both earnings and sales [1] Company Performance Pfizer (PFE) - Pfizer has consistently exceeded earnings expectations in the last four quarters, with an average earnings surprise of 43.49% [6] - The Zacks Consensus Estimate for second-quarter sales and earnings is $13.78 billion and 58 cents per share, respectively [6] - Higher sales from products like Vyndaqel and Padcev are expected to offset weaker sales from Prevnar and Ibrance [8] Eli Lilly (LLY) - Eli Lilly's performance has been mixed, exceeding earnings expectations in two of the last four quarters, with an average earnings surprise of 6.69% [11] - The Zacks Consensus Estimate for second-quarter sales and earnings stands at $14.75 billion and $5.61 per share, respectively [11] - Strong demand for Mounjaro and Zepbound is anticipated to drive top-line growth [12] Amgen (AMGN) - Amgen has shown strong performance, beating earnings estimates in each of the last four quarters, with an average earnings surprise of 8.34% [14] - The Zacks Consensus Estimate for second-quarter sales and earnings is $8.86 billion and $5.26 per share, respectively [14] - Sales growth is expected to be driven by products like Evenity and Repatha, despite price declines due to higher rebates [15] Gilead Sciences (GILD) - Gilead's performance has been mixed, with earnings beating estimates in three of the last four quarters, averaging a surprise of 16.48% [17] - The Zacks Consensus Estimate for second-quarter sales and earnings is $6.95 billion and $1.95 per share, respectively [17] - Increased demand for HIV therapies like Biktarvy is expected to boost sales [18] Novo Nordisk (NVO) - Novo Nordisk's performance has been mixed, with earnings beating estimates in one of the last four quarters, delivering an average surprise of 0.02% [20] - The Zacks Consensus Estimate for second-quarter sales and earnings is $11.79 billion and 93 cents per share, respectively [20] - The company lowered its 2025 sales and operating profit growth outlook due to weaker momentum in key markets for its semaglutide-based drugs [21]

Core Insights - Amgen is scheduled to release its earnings on August 5, 2025, with historical trends indicating a tendency for negative one-day returns post-announcement [2][3] - Analysts project earnings of $5.28 per share and revenue of $8.91 billion, compared to $4.97 per share and $8.39 billion in the same quarter last year [3] - The company has a market capitalization of $160 billion and reported $34 billion in revenue over the past twelve months, resulting in $7.4 billion in operating profits and a net income of $5.9 billion [4] Historical Performance - Over the past five years, Amgen's stock has declined 58% of the time following earnings announcements, with a median drop of -2.8% and a maximum one-day negative return of -7.2% [2][7] - Positive one-day returns occurred approximately 42% of the time, with the percentage increasing to 45% when considering the last three years [7] - The median of the eight positive returns was 3.6%, while the median of the eleven negative returns was -2.8% [7] Trading Strategies - Event-driven traders can utilize historical trends to inform their positioning ahead of earnings releases [6] - A strategy involves assessing the correlation between immediate and medium-term returns post-earnings to guide trading decisions [6][8] - The correlation between one-day and five-day returns can indicate potential trading positions, particularly if the one-day return is positive [8]

Core Points - Amgen's Board of Directors declared a dividend of $2.38 per share for Q3 2025, payable on September 12, 2025, to stockholders of record as of August 22, 2025 [1] - Amgen is a leader in biotechnology, focusing on innovative medicines for serious diseases, with a strong pipeline targeting cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases [2] - The company has received multiple accolades, including being named one of the "World's Most Innovative Companies" and "America's Best Large Employers," and is part of the Dow Jones Industrial Average and Nasdaq-100 Index [3] Company Overview - Amgen has over 40 years of experience in the biotechnology industry and utilizes advanced technology and human genetic data to drive innovation [2] - The company is recognized for its commitment to research and development, maintaining a broad and deep pipeline of medicines [2] Recognition and Market Position - In 2024, Amgen was recognized by Fast Company and Forbes for its innovation and employer status, highlighting its strong market position [3] - As a component of major stock indices, Amgen is considered one of the largest and most innovative non-financial companies [3]

In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X, LinkedIn ...

Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period. Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a str ...

Summary of the Conference Call Company and Industry Overview - The conference call primarily discusses **ASP Isotopes** and its collaboration with **ISOBio** in the field of **radiotherapeutics** and **nuclear medicine** [2][12][32]. Core Points and Arguments 1. **Focus on Radiotherapeutics**: ISOBio is concentrating on developing a new class of radiotherapeutics known as **Antibody Isotope Conjugates (AICs)**, which aim to minimize off-target toxicities while effectively targeting tumors [13][15]. 2. **Historical Context**: The evolution of cancer treatment has progressed from small molecule cytotoxics to antibodies, and now to **Antibody Drug Conjugates (ADCs)** and **Radioligand Therapies (RLTs)**, with the latter expected to grow into a multibillion-dollar market [5][9][49]. 3. **Manufacturing Challenges**: A significant barrier in the development of radiotherapeutics has been the supply chain issues related to obtaining isotopes. ISOBio aims to mitigate these risks through its partnership with ASP and PET Labs, which will facilitate the manufacturing of isotopes in the U.S. [10][11][18][39]. 4. **Market Potential**: The market for radiotherapeutics is projected to exceed **$13 billion** by 2033, with more than a dozen approved drugs anticipated [49][50]. 5. **Strategic Partnerships**: The collaboration between ISOBio, ASP, and PET Labs is designed to ensure a reliable supply of isotopes, which is crucial for clinical trials and product development [37][54]. Additional Important Content 1. **Clinical Development Timeline**: The timeline for clinical trials in radiotherapeutics is longer than for ADCs, often taking an additional **six to nine months** due to complexities in the manufacturing and regulatory processes [66]. 2. **Regulatory Compliance**: Establishing a new radiopharmacy can take approximately **two years**, including equipment ordering and regulatory compliance [61][62]. 3. **Environmental Considerations**: The enrichment processes used by ASP are noted to be environmentally friendly, with low or zero waste [38]. 4. **Future Outlook**: The call emphasizes the potential for ISOBio to become a major player in the radiotherapeutics market, with plans for clinical development within the next **one to two years** [54][55]. 5. **M&A Strategy**: ISOBio plans to pursue mergers and acquisitions to enhance its capabilities and product offerings in the radiotherapeutics space [71][72]. This summary encapsulates the key points discussed during the conference call, highlighting the strategic direction of ISOBio and its partnership with ASP Isotopes in the rapidly evolving field of radiotherapeutics.

Core Viewpoint - Amgen (AMGN) is expected to exceed earnings expectations for Q2 2025, with consensus estimates for sales at $8.86 billion and earnings per share at $5.25, following a previous quarter where it beat earnings expectations by 17.8% [2][9]. Sales Performance - Strong volume growth from products such as Evenity, Repatha, and Blincyto is anticipated to drive sales, although prices are expected to decline due to increased rebates [3][9]. - The Zacks Consensus Estimate for sales of Evenity, Repatha, and Blincyto is $478 million, $673 million, and $385 million, respectively [3]. Product Insights - Sales of RANKL antibodies, Prolia, and Xgeva are expected to benefit from volume growth, despite price declines. However, the expiration of patents for Prolia and Xgeva in the U.S. in February 2025 may lead to significant sales erosion in the latter half of 2025 [5]. - Newer drugs like Tezspire and Tavneos are projected to contribute positively to top-line growth, with consensus estimates of $320 million and $102 million, respectively [6]. Competitive Landscape - Kyprolis is facing competitive pressure, which likely affected its volume growth in Q1 and is expected to continue in Q2, with consensus estimates for sales at $370 million [7]. - Enbrel sales are likely to decline due to lower prices, while Otezla is expected to see gains from volume growth, with estimates of $534 million for Otezla and $805 million for Enbrel [8]. Recent Developments - Sales of rare disease drugs from the acquisition of Horizon are expected to improve in Q2, following lower-than-expected sales in Q1 due to inventory changes [10]. - New biosimilars launched, such as Wezlana and Pavblu, are anticipated to drive sales growth, although fluctuations in quarterly sales are expected [12][13]. Earnings Surprise History - Amgen has a strong earnings surprise history, with an average surprise of 8.34% over the last four quarters and a stock increase of 18.4% year-to-date compared to a 1.9% increase in the industry [14]. Earnings Prediction Model - The earnings prediction model indicates a likely earnings beat for Amgen, with an Earnings ESP of +1.19% and a Zacks Rank of 3 [15][17].

Technical Analysis - Amgen Inc. (AMGN) has reached a significant support level and is considered a good pick for investors from a technical perspective due to a "golden cross" formation, where the 50-day simple moving average has broken above the 200-day moving average [1] - A golden cross is a bullish chart pattern indicating a potential breakout, characterized by a short-term moving average crossing above a long-term moving average [1][2] Market Performance - AMGN has moved 7.9% higher over the last four weeks, suggesting a positive trend [3] - The company currently holds a 3 (Hold) rating on the Zacks Rank, indicating a neutral outlook [3] Earnings Expectations - There have been 6 upward revisions in earnings expectations for the current quarter, with no downward revisions in the past 60 days, which supports the bullish sentiment [3] - The Zacks Consensus Estimate for earnings has also increased, further reinforcing the positive outlook for AMGN [3][4] Investment Outlook - With a combination of favorable earnings estimate revisions and a key technical level being hit, AMGN is positioned for potential gains in the near future [4]